drugset / Trial / NCT06632262
A Phase 2 Clinical Study of ABSK061 and ABSK043
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Timeline
- Start
- 2024-11-13
- Primary completion
- 2029-11-30
- Completion
- 2030-06-30